WO2003001883A3 - Gaba b1a receptor disruptions, compositions and methods relating thereto - Google Patents

Gaba b1a receptor disruptions, compositions and methods relating thereto

Info

Publication number
WO2003001883A3
WO2003001883A3 PCT/US2002/020270 US0220270W WO2003001883A3 WO 2003001883 A3 WO2003001883 A3 WO 2003001883A3 US 0220270 W US0220270 W US 0220270W WO 2003001883 A3 WO2003001883 A3 WO 2003001883A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
gaba
invention
methods
present
provides
Prior art date
Application number
PCT/US2002/020270
Other languages
French (fr)
Other versions
WO2003001883A2 (en )
Inventor
Robert G Wisotzkey
Original Assignee
Deltagen Inc
Robert G Wisotzkey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/075Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

The present invention relates to compositions and methods relating to the characterization, function, and uses of GABA-B1A. Specifically, the present invention provides transgenic animals comprising disruptions in GABA-B1A receptors. The present invention also provides methods of identifying agents that modulate GABA-B1A, useful models, and potential for various disease states and disease conditions.
PCT/US2002/020270 2001-06-26 2002-06-25 Gaba b1a receptor disruptions, compositions and methods relating thereto WO2003001883A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US30110201 true 2001-06-26 2001-06-26
US60/301,102 2001-06-26

Publications (2)

Publication Number Publication Date
WO2003001883A2 true WO2003001883A2 (en) 2003-01-09
WO2003001883A3 true true WO2003001883A3 (en) 2004-01-22

Family

ID=23161949

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/020270 WO2003001883A3 (en) 2001-06-26 2002-06-25 Gaba b1a receptor disruptions, compositions and methods relating thereto

Country Status (2)

Country Link
US (1) US20030056238A1 (en)
WO (1) WO2003001883A3 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8958881B2 (en) 2005-08-19 2015-02-17 Brainsgate Ltd. Neuroprotective electrical stimulation
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US7561919B2 (en) * 2002-11-14 2009-07-14 Brainsgate Ltd. SPG stimulation via the greater palatine canal
US7146209B2 (en) * 2000-05-08 2006-12-05 Brainsgate, Ltd. Stimulation for treating eye pathologies
US7120489B2 (en) 2000-05-08 2006-10-10 Brainsgate, Ltd. Method and apparatus for stimulating the sphenopalatine ganglion to modify properties of the BBB and cerebral blood flow
US7117033B2 (en) * 2000-05-08 2006-10-03 Brainsgate, Ltd. Stimulation for acute conditions
WO2003090599A3 (en) * 2002-04-25 2004-11-25 Brainsgate Ltd Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head
US7684859B2 (en) * 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
US7636597B2 (en) * 2002-11-14 2009-12-22 Brainsgate, Ltd. Surgical tools and techniques for stimulation
US20090299418A1 (en) * 2004-08-23 2009-12-03 Brainsgate Ltd. Concurrent bilateral spg modulation
US20090210026A1 (en) * 2006-08-17 2009-08-20 Brainsgate Ltd. Spg stimulation for enhancing neurogenesis and brain metabolism
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HIRST ET AL.: "Molecular and pharmacological characterisation of the GABAB1 knockout mouse", SOC. NEUROSCI., vol. 27, no. 2, 2001, pages 1854, XP002968371 *
MARTIN AND OLSEN: "GABA in the Nervous System", 2000, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, PA, article OLSEN ET AL.: "Function of GABAA receptors: insights from mutant and kncockout mice", pages: 81 - 96, XP002968370 *
PANGALOS ET AL.: "Epileptogenesis and pre-pulse inhibition in GABAB1 deficient mice", SOCIETY NEUROSCI., vol. 27, no. 2, 2001, pages 1855, XP002968372 *
PROSSER ET AL.: "Epileptogenesis and enhanced prepulse inhibition in GABA-B1-deficient mice", MOL. CELLUAR NEUROSCI., vol. 17, June 2001 (2001-06-01), pages 1059 - 1070, XP002968373 *
SANGER ET AL.: "GABA(B) receptor function in the ileum and urinary bladder of wildtype and GABA)B1) subunit in null mice", AUTON. AUTACOID PHARMACOL., vol. 22, no. 3, June 2002 (2002-06-01), pages 147 - 154, XP002968374 *
SULLIVAN ET AL.: "Coexpression of full-length gamma-aminobutyric acid-B (GABA-B) receptors with truncated receptors with truncated receptors and metabotropic glutamate receptor 4 supports the GANA-B heterodimer as the functional receptor 1", J. PHARMACOL. AND EXP. THERAPEUTICS, vol. 293, no. 2, 2000, pages 460 - 467, XP002968375 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8958881B2 (en) 2005-08-19 2015-02-17 Brainsgate Ltd. Neuroprotective electrical stimulation

Also Published As

Publication number Publication date Type
WO2003001883A2 (en) 2003-01-09 application
US20030056238A1 (en) 2003-03-20 application

Similar Documents

Publication Publication Date Title
WO2005123703A8 (en) Alkynyl derivatives as modulators of metabotropic glutamate receptors
WO2005103050A3 (en) Azaindoles useful as inhibitors of rock and other protein kinases
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
WO2008051797A3 (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
WO2005014650A3 (en) Antibodies specific for sclerostin and methods for increasing bone mineralization
WO2006083936A3 (en) Anti-ephb2 antibodies and methods using same
USD458856S1 (en) Series light-string troubleshooting tool
WO2007001466A3 (en) Peptidomimetic somatostatin receptor subtype 2 ligands and pet imaging agents
WO2007034196A3 (en) Imaging agents comprising silicon
USD490446S1 (en) Laser marking device
WO2006004910A3 (en) Improved bispecific antibodies
WO2005009389A3 (en) Anaplastic lymphoma kinase modulators and methods of use
WO2002099074A8 (en) Slc7s as modifiers of the p53 pathway and methods of use
CA2462955A1 (en) Herbicide compositions comprising imidazolinone acid
Winkler Modeling the Modeling
WO2006096489A3 (en) Anti-m-csf antibody compositions having reduced levels of endotoxin
WO2005000807A3 (en) Benzodiazepine cgrp receptor antagonists
Staff 2002 Specula.
WO2002061075A1 (en) Novel g protein-coupled receptor protein and dna thereof
Amsha The Term “Theatre” between Egypt and Levant
WO2004090145A3 (en) Compounds and methods to enhance raav transduction
WO2004080406A3 (en) Therapeutic compositions
WO2003033672A3 (en) Nr3b nmda receptor subunit compositions and related methods
Patel Gujarat rajyana prathmik adhyapan mandirona prashikshanarthio mate bhasha samarthy kasotini rachna ane pramanikaran

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
WWW Wipo information: withdrawn in national office

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: JP